Table 2.
The characteristics of the CML patients with COVID-19 and control group.
| Characteristics | CML(N = 16) | Control group(N = 48) | P value |
|---|---|---|---|
| Gender | |||
| Female, n (%) | 10 (62.5%) | 31 (64,6%) | 0,9 |
| Male, n (%) | 6 (37,5%) | 17 (35,4%) | |
| Age (years) | 51 (27–87) | 56 (20–87) | 0.4 |
| Comorbidity | |||
| Hypertension | 7 (43,8%) | 21 (43,8%) | 1 |
| Diabetes mellitus | 3 (18,8%) | 10 (20,8%) | 1 |
| Cardiovascular diseases | 5 (31,3%) | 12 (25%) | 0,8 |
| Respiratory system diseases | 4 (25%) | 11 (22,9%) | 1 |
| Chronic renal diseases | 2 (12,5%) | 3 (6,3%) | 0,6 |
| Cerebrovascular diseases | 1 (%6,3) | 2 (%4,2) | 1 |
| Additional treatment, n (%) | |||
| Favipiravir | 4 (25%) | 14 (29,2%) | 1 |
| Oseltamivir | 9 (56,3%) | 20 (41,7%) | 0,4 |
| Lopinavir/ritonavir | 1 (6,3%) | 0 | 0,2 |
| Hydroxychloroquine | 13 (81,3%) | 33 (68,8%) | 0,5 |
| High dose Vitamin C | 1 (6,3%) | 6 (12,5%) | 0,7 |
CML: chronic myeloid leukemia.